| Ali Ann Rowland, APRN-CNP | |
|
901 W Main St, Durant, OK 74701-5070 | |
| (580) 634-2931 | |
| Not Available |
| Full Name | Ali Ann Rowland |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 901 W Main St, Durant, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316601875 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 205873 (Oklahoma) | Secondary |
| 363L00000X | Nurse Practitioner | 1098492 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Williams Medical Group Practice Llc | 3375832157 | 122 |
| Williams Medical Group Practice Llc | 3375832157 | 122 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
A recent study led by the researchers from Johns Hopkins University reveals multiple and diverse introductions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States National Capital Region during the initial phase of coronavirus disease 2019 (COVID-19) pandemic. The study is currently available on the medRxiv* preprint server.
Advances in technology allow scientists to measure intricate details about the human body that greatly enhance understanding of health, disease and aging.
Two U.S. Department of Health and Human Services agencies will collaborate in the most comprehensive study to date of prescription medications used to treat attention deficit hyperactivity disorder (ADHD) and the potential for increased risk of heart attack, stroke or other cardiovascular problems.
› Verified 3 days ago
| Entity Name | Williams Medical Group Practice Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346608809 PECOS PAC ID: 3375832157 Enrollment ID: O20181228001300 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
A recent study led by the researchers from Johns Hopkins University reveals multiple and diverse introductions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States National Capital Region during the initial phase of coronavirus disease 2019 (COVID-19) pandemic. The study is currently available on the medRxiv* preprint server.
Advances in technology allow scientists to measure intricate details about the human body that greatly enhance understanding of health, disease and aging.
Two U.S. Department of Health and Human Services agencies will collaborate in the most comprehensive study to date of prescription medications used to treat attention deficit hyperactivity disorder (ADHD) and the potential for increased risk of heart attack, stroke or other cardiovascular problems.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ali Ann Rowland, APRN-CNP 93 Swan Ln, Durant, OK 74701-1032 Ph: () - | Ali Ann Rowland, APRN-CNP 901 W Main St, Durant, OK 74701-5070 Ph: (580) 634-2931 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
A recent study led by the researchers from Johns Hopkins University reveals multiple and diverse introductions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States National Capital Region during the initial phase of coronavirus disease 2019 (COVID-19) pandemic. The study is currently available on the medRxiv* preprint server.
Advances in technology allow scientists to measure intricate details about the human body that greatly enhance understanding of health, disease and aging.
Two U.S. Department of Health and Human Services agencies will collaborate in the most comprehensive study to date of prescription medications used to treat attention deficit hyperactivity disorder (ADHD) and the potential for increased risk of heart attack, stroke or other cardiovascular problems.
› Verified 3 days ago
Darci Lynn Bowen, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1801 Chukka Hina, Durant, OK 74701 Phone: 580-920-2100 | |
Jodi Robinson, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1400 Bryan Dr, Suite 303, Durant, OK 74701 Phone: 580-931-2227 Fax: 580-931-2057 | |
Duncan Kovash, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1901 Chukka Hina, Durant, OK 74701 Phone: 580-920-2100 | |
Mrs. Jennifer Renee Nelson, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1708 Delivery Lane, Durant, OK 74701 Phone: 580-924-5622 Fax: 580-745-5060 | |
Mrs. Johnette L Routh, A.R.N.P. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1400 Bryan Dr, #300, Durant, OK 74702 Phone: 580-924-1700 Fax: 580-924-1736 | |
Mrs. Jessica Laine Williams, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1400 Bryan Dr Ste 208, Durant, OK 74701 Phone: 580-920-9063 | |
Amanda Robertson, APRN, CNP, PMHNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2701 W University Blvd, Durant, OK 74701 Phone: 580-740-4053 |